Loading...
Chemotherapy-Induced Upregulation of Somatostatin Receptor-2 Increases the Uptake and Efficacy of (177)Lu-DOTA-Octreotate in Neuroendocrine Tumor Cells
SIMPLE SUMMARY: The peptide receptor radionuclide therapy (PRRT) with (177)Lu-DOTA-octreotate (LuTate) is recommended for neuroendocrine tumors (NETs) which overexpress somatostatin receptors (SSTR). A combination of LuTate with chemotherapy improves its objective response in NET patients, and here...
Na minha lista:
| Udgivet i: | Cancers (Basel) |
|---|---|
| Main Authors: | , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
MDPI
2021
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7828052/ https://ncbi.nlm.nih.gov/pubmed/33435224 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13020232 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|